Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rFVIIIFc immune tolerance induction in severe hemophilia A patients with inhibitors after prior ITI failure
2017-000065-73Phase 4Completed
- Sponsor
- Sobi
- Start
- Apr 2017
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of efmoroctocog alfa in hemophilia A, sponsored by Sobi. Primary endpoint: ITI success. Started Apr 2017; status: completed.
02
Drugs
efmoroctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2017-000065-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000065-73.